GlassScriptPhysician profile
Amy S Pappert
NPI 1598723884
$2,352.24
in general payments reported to CMS, 2019-2025
23 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $289 · 2021: $417 · 2022: $341 · 2023: $122 · 2024: $351 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.60 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $249.00 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $238.89 | 2021-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $236.16 | 2020-2021 | |
| Abbvie INC. | $216.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.80 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $163.06 | 2020-2025 | |
| Incyte Corporation | $159.72 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $150.10 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $113.49 | 2020 | |
| Dermira, INC. | $105.10 | 2019 | |
| Almirall LLC | $104.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.94 | 2023-2025 | Sotyktu |
| Ucb, INC. | $46.90 | 2021-2024 | Bimzelx |
| Genzyme Corporation | $45.66 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $42.54 | 2020-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.39 | 2024 | Spevigo |
| Organon LLC | $32.66 | 2024-2025 | Vtama |
| Biofrontera INC. | $31.92 | 2019-2025 | |
| Nobelpharma America, LLC | $24.21 | 2023 | |
| Baxter Healthcare | $20.76 | 2022 | |
| Dermavant Sciences, INC. | $17.14 | 2023 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $16.99 | 2024 | Valchlor |
| Celgene Corporation | $14.57 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Pappert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.